Scott A. Armstrong
Scott A. Armstrong | |
---|---|
Born | Lawton, Oklahoma, US |
Academic background | |
Education | BSc, chemistry, 1989, University of Oklahoma MD, PhD, 1994, University of Texas Southwestern Medical Center |
Thesis | Molecular and biochemical characterization of Rab geranylgeranyl transferase (1994) |
Academic work | |
Institutions | Dana-Farber Cancer Institute Memorial Sloan Kettering Cancer Center Weill Cornell Medical College |
Website | armstronglab |
Scott Allen Armstrong is an American pediatric oncologist. Armstrong and his team were the first to isolate rare leukemia stem cells in a mouse model of leukemia.
Early life and education[]
Armstrong was raised in Lawton, Oklahoma and Duncan, Oklahoma and attended Duncan High School. As a student, he was encouraged to apply for the Oklahoma Medical Research Foundation's Sir Alexander Fleming Scholar Program which he described as a "huge impact on my life."[1] Following high school, Armstrong majored in chemistry at the University of Oklahoma and completed a dual medical degree/PhD program at the University of Texas Southwestern Medical Center.[2] Following this, Armstrong was the recipient of the 2000 American Society of Hematology Scholar Award Fellowship.[3]
Career[]
As an instructor in pediatric oncology at the Dana-Farber Cancer Institute, Armstrong's scientific focus was on the genetic abnormalities that are common in childhood leukemias. In 2001, he was the lead investigator on a study researching gene expression patterns to treat cancer.[4][5] The following year, Armstrong published a landmark study in Nature Genetics which demonstrated that mixed-lineage leukemia (MLLs) exhibited a unique expression signature. A few years later, he also showed how the FMS-like tyrosine kinase-3 was highly expressed and often mutated in MLLs.[6] Armstrong and his team also became the first to isolate rare leukemia stem cells in a mouse model of leukemia.[7]
As a result of his genome-wide technologies to characterize the molecular pathways responsible for leukemia development, Armstrong was elected a member of the American Society for Clinical Investigation[8] and was the recipient of the 2011 Paul Marks Prize for Cancer Research.[7] Later that year, his research team collaborated with a biotechnology company to develop a drug that could deactivate cancer-promoting genes and halt the growth of cancer.[9] The following year, Armstrong was named the incumbent of the Grayer Family Chair at the Memorial Sloan Kettering Cancer Center (MSK).[10] By 2014, Armstrong became the Director of the Leukemia Center at MSK, where he also serves as Vice-Chair for Basic and Translational Research in Pediatrics and as a full member of the MSK Cancer Biology and Genetics Program. As a result of his "exceptional work in leukemia research and cancer stem cell biology," Armstrong was the recipient of the 2014 American Society of Hematology William Dameshek Prize.[6]
Armstrong eventually left MSK in 2016 to become the Chair of the Department of Pediatric Oncology at the Dana-Farber Cancer Institute, and the David G. Nathan Professor of Pediatrics at the Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School. He also served as Associate Chief of the Division of Hematology and Oncology at Boston Children's Hospital.[11] While serving in these roles, Armstrong was elected a member of the National Academy of Medicine[12] and awarded the 2019 Tobias Award Lecture from the International Society for Stem Cell Research.[13]
References[]
- ^ Stevens, Courtney (January 16, 2010). "Offering a chance to change the world". The Daily Oklahoman. Retrieved May 28, 2021 – via newspapers.com.
- ^ "Armstrong completes M.D./Ph.D degrees". Okmulgee Daily Times. June 16, 1996. Retrieved May 28, 2021 – via newspapers.com.
- ^ "Scott Armstrong, MD, PhD: 2000 ASH Scholar". hematology.org. Retrieved May 28, 2021.
- ^ "Diagnosis by database shows promise". Harvard Gazette. December 14, 2001. Retrieved May 28, 2021.
- ^ "Scientists using gene chips identify unique form of leukemia". Harvard Gazette. December 3, 2001. Retrieved May 28, 2021.
- ^ a b "ASH honors Scott Armstrong, M.D., Ph.D., with 2014 William Dameshek Prize". eurekalert.org. Eurekalert. July 22, 2014. Retrieved May 28, 2021.
- ^ a b "Three Young Investigators Named Winners of Paul Marks Prize for Cancer Research". mskcc.org. September 20, 2011. Retrieved May 28, 2021.
- ^ "Scott A. Armstrong, MD, PhD". the-asci.org. Retrieved May 28, 2021.
- ^ "Epigenetic pathway and new drug show promise in reversing a hard-to-treat childhood cancer". dana-farber.org. July 11, 2011. Retrieved May 28, 2021.
- ^ "Scott Armstrong and Kitai Kim Named to Endowed Chairs". mskcc.org. November 1, 2012. Retrieved May 28, 2021.
- ^ "Scott A. Armstrong to lead Department of Pediatric Oncology at Dana-Farber Cancer Institute". newswise.com. March 29, 2016. Retrieved May 28, 2021.
- ^ "Three Dana-Farber faculty members elected to National Academy of Medicine". dana-farber.org. October 16, 2017. Retrieved May 28, 2021.
- ^ "ISSCR Announces 2019 Award Recipients". isscr.org. February 8, 2019. Retrieved May 28, 2021.
- Living people
- Physicians from Oklahoma
- People from Duncan, Oklahoma
- University of Oklahoma alumni
- University of Texas Southwestern Medical Center alumni
- Members of the American Society for Clinical Investigation
- Members of the National Academy of Medicine